• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Letter to Editor-response: placebo response rates.致编辑的回信——安慰剂反应率
EClinicalMedicine. 2023 Feb 14;56:101852. doi: 10.1016/j.eclinm.2023.101852. eCollection 2023 Feb.
2
Authors' response to letter to the editor, letter to the editor: Authors' response to letter to the editor: Safety concerns with human papilloma virus immunization in Japan: Analysis and evaluation of Nagoya City's surveillance data for adverse events.作者对编辑来信的回复，编辑来信：作者对编辑来信的回复：日本人类乳头瘤病毒免疫接种的安全性问题：名古屋市不良事件监测数据的分析与评估
Jpn J Nurs Sci. 2020 Jan;17(1):e12310. doi: 10.1111/jjns.12310. Epub 2019 Dec 2.
3
Letter to the Editor - The implications of the professionalization of health promotion in Canada: a response to JR Graham's letter to the editor.给编辑的信——加拿大健康促进专业化的影响：对 JR Graham 给编辑的信的回应。
Health Promot Chronic Dis Prev Can. 2017 May;37(5):172-173. doi: 10.24095/hpcdp.37.5.05.
4
Letter to the Editor.致编辑的信。
Am Stat. 2019;73(3):312. doi: 10.1080/00031305.2018.1537894. Epub 2019 Aug 5.
5
Letter #1 Response to letter to Editor by Dr. Sarkar et al. for' who said differentiating preeclampsia from COVID-19 infection was easy? Refers to PII: S2210-7789(21)00539-0 Letter #2 Response to letter to Editor by Dr. Hantoushzadeh et al. for' is COVID-19 disease a risk factor for preeclampsia? Should aspirin be considered for prophylaxis of preeclampsia in these patients?' Refers to PII: S2210-7789(21)00538-9.信件1：对Sarkar博士等人致编辑的信的回复，信的主题为“谁说区分先兆子痫和新冠病毒感染很容易？”，涉及编号：S2210 - 7789(21)00539 - 0 信件2：对Hantoushzadeh博士等人致编辑的信的回复，信的主题为“新冠病毒疾病是先兆子痫的危险因素吗？这些患者是否应考虑使用阿司匹林预防先兆子痫？”，涉及编号：S2210 - 7789(21)00538 - 9
Pregnancy Hypertens. 2022 Mar;27:94-95. doi: 10.1016/j.preghy.2021.11.002. Epub 2021 Nov 25.
6
How to write an editorial letter?如何撰写编辑信函？
Turk J Urol. 2013 Sep;39(Suppl 1):41-3. doi: 10.5152/tud.2013.053.
7
Letter to the Editor Re: Author's Response to Letter to the Editor.致编辑的信：关于作者对致编辑信件的回复
Arch Phys Med Rehabil. 2020 Jun;101(6):1096-1097. doi: 10.1016/j.apmr.2019.12.022. Epub 2020 Mar 7.
8
Response Letter to the Editor in Reference to Letter to the Editor about "Does Overall Catastrophic Health Care Expenditure Make Sense"?针对关于“总体灾难性医疗支出是否合理？”的读者来信给编辑的回复信
Iran J Public Health. 2018 Aug;47(8):1230-1231.
9
Response to Letter to the Editor Regarding "Probiotic Administration in Infants With Gastroschisis: A Pilot Randomized Placebo-Controlled Trial".对关于“先天性腹裂婴儿的益生菌给药：一项随机安慰剂对照试验”的致编辑信的回复
J Pediatr Gastroenterol Nutr. 2016 Dec;63(6):e210. doi: 10.1097/MPG.0000000000001392.
10
Response to the letter to the editor by L.A. Avila.对L.A. 阿维拉致编辑信的回复。
Pain. 2013 Nov;154(11):2572. doi: 10.1016/j.pain.2013.06.048. Epub 2013 Aug 21.

本文引用的文献

1
Objective response rate of placebo in randomized controlled trials of anticancer medicines.抗癌药物随机对照试验中安慰剂的客观缓解率。
EClinicalMedicine. 2022 Nov 24;55:101753. doi: 10.1016/j.eclinm.2022.101753. eCollection 2023 Jan.
2
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.一项评估regorafenib 对比安慰剂治疗晚期/转移性、治疗后复发脂肪肉瘤的随机、双盲、安慰剂对照、II 期研究（SARC024 研究）结果。
Oncologist. 2020 Nov;25(11):e1655-e1662. doi: 10.1634/theoncologist.2020-0679. Epub 2020 Aug 20.
3
Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors.非甾体抗炎药在治疗腹外硬纤维瘤中的作用
Clin Orthop Surg. 2018 Jun;10(2):225-233. doi: 10.4055/cios.2018.10.2.225. Epub 2018 May 18.
4
Effective treatment of aggressive fibromatosis with celecoxib guided by genetic testing.基于基因检测的塞来昔布靶向治疗侵袭性纤维瘤病
Cancer Biol Ther. 2017 Oct 3;18(10):757-760. doi: 10.1080/15384047.2017.1373215. Epub 2017 Sep 7.

Letter to Editor-response: placebo response rates.

作者信息

Gyawali Bishal

机构信息

Department of Oncology, Queen's University, Kingston, Ontario, Canada.

Cancer Centre of Southeastern Ontario, Kingston, Ontario, Canada.

出版信息

EClinicalMedicine. 2023 Feb 14;56:101852. doi: 10.1016/j.eclinm.2023.101852. eCollection 2023 Feb.

DOI:10.1016/j.eclinm.2023.101852
PMID:36851987
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9958350/
Abstract
摘要